Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesAllergy/Clinical ImmunologyPremera Bluecross omalizumab Coverage Policy Updat…
    Ask Trek AI about this page
    ModifiedPremera BluecrossPolicy 5.01.513

    Omalizumab Products (Xolair, Omlyclo) coverage

    Customize your policy alerts

    Sign up for Premera Bluecross Policy 5.01.513 alerts

    Get alerted when Policy 5.01.513 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy defines medical necessity, site-of-service review, documentation, coding, and approval durations for omalizumab products (Xolair and Omlyclo) across indications including moderate-to-severe asthma, chronic idiopathic urticaria, CRSwNP, and IgE-mediated food allergy; it applies to providers submitting pharmacy or medical benefit requests to Premera Bluecross.

    Policy Summary
    PayerPremera Bluecross
    PolicyOmalizumab Products (Xolair, Omlyclo) coverage
    Policy CodePolicy 5.01.513
    Change TypeClinical and operational updates (authorization length, dosing limits, combination exclusions)
    Effective DateAug 1, 2026
    Last ReviewJul 14, 2026
    Next Review DateJul 14, 2026
    Key ActionSubmit prior authorization with documentation of pretreatment total serum IgE and body weight and request initial approval for up to 12 months per updated policy.
    SourceLink
    POLICY UPDATE CHANGES

    Updated initial authorization for all reviews from 6 months to 12 months.

    Updated indication for asthma to add Exdensur (depemokimab-ulaa) to list of medications not to be used concurrently.

    Updated chronic idiopathic urticaria dose limit to 600 mg every 2 weeks.

    Updated asthma criteria to use maximum tolerated doses of an inhaled corticosteroid instead of maximum doses.

    Updated asthma diagnostic criteria to include two or more exacerbations in previous 12 months requiring oral corticosteroids, or one or more exacerbations requiring hospitalization/ED/urgent care, or FEV1 <80% predicted, or dependence on oral corticosteroids/worsening on taper.

    Policy title updated from Xolair (omalizumab) to Omalizumab Products and Omlyclo (omalizumab-igec) was added with the same criteria as Xolair.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    12 monthsinitial authorization duration
    600 mgCIU dose limit
    750 mgasthma max dose q4w
    J2357, Q5154HCPCS codes
    Ages 1+ to 18+age ranges covered
    >=3in-office doses before self-admin

    Coverage Criteria for Omalizumab Products

    Moderate to severe persistent allergic asthma (site-of-service criteria applied)

    Covered when ALL of the following are met

    Age: Individual is aged 6 years or older>=6 yrs

    Site-of-service review may apply

    Controller therapy: Using maximum tolerated doses of an inhaled corticosteroid AND using an inhaled long-acting beta-agonist (LABA)
    Asthma severity markers (one required): One or more of: two or more exacerbations in prior 12 months requiring oral corticosteroids OR one or more exacerbations requiring hospitalization/ED/urgent care in prior 12 months OR FEV1 <80% predicted OR FEV1/FVC <0.80 OR asthma that worsens upon tapering of oral corticosteroid therapy
    Allergy testing: Positive skin test or in vitro reactivity (RAST) to a perennial aeroallergen when skin test not appropriate
    IgE and weight limits: Total serum IgE within age-based ranges (30–1,300 IU/mL for ages 6–11; 30–700 IU/mL for age ≥12) AND weight between 20 kg and 150 kg
    Dose cap: Dose limited to 750 mg every 4 weeks based on serum IgE and body weight per prescribing table
    Concomitant biologics restriction: Not used in combination with listed biologics when used for asthma (examples: reslizumab, dupilumab, depemokimab-ulaa/Exdensur, benralizumab, mepolizumab, tezepelumab/Tezspire)
    Prescriber: Prescribed by or in consultation with an allergist, immunologist, or pulmonologist

    Severe chronic idiopathic urticaria

    Covered when ALL of the following are met

    Age: Individual is aged 12 years or older
    Exclude other causes: No evidence of another cause of the urticarial reaction
    Duration: At least 6 weeks of symptoms (chronic urticaria, itching, hives or angioedema)
    Prior therapy: Failed or intolerant to at least 2 H1-antihistamines at high doses (≥2x and up to 4x normal dosing) or maximum tolerated dose
    Concomitant therapy: Plans to continue treatment with a low dose of H1 antihistamines while on therapy

    Chronic rhinosinusitis with nasal polyps (CRSwNP)

    Covered when ALL of the following are met

    Age: Individual is aged 18 years or older
    Symptoms (>=2 required): Has at least 2 of: facial pressure/pain; moderate–severe nasal congestion/discharge/obstruction; significant loss of smell
    Pretreatment IgE: Pretreatment total serum IgE ≥30 IU/mL
    Weight: Weighs between 30 kg and 150 kg
    Objective confirmation: Diagnosed with inadequately controlled bilateral CRSwNP confirmed by physical exam, sinus CT, or nasal endoscopy

    IgE-mediated food allergy (to reduce Type I allergic reactions)

    Covered when ALL of the following are met

    Age: Individual is aged 1 year or older
    Diagnosis: Diagnosed with an IgE-mediated food allergy demonstrated by signs/symptoms of a systemic allergic reaction shortly after known ingestion AND a positive skin prick test OR positive serum specific IgE to one or more foods
    Concomitant measures: Used in conjunction with a diet that avoids food allergens and the individual has been prescribed an epinephrine auto-injector
    Concomitant therapy restriction: Not used concomitantly with Palforzia (peanut allergen powder)
    Dose cap:

    Asthma — general positioning: adjunct for moderate to severe allergic asthma inadequately controlled despite standard therapies

    Covered when used as an adjunct for individuals with moderate to severe allergic asthma inadequately controlled despite standard therapies

    Asthma placement criteria: Use in individuals with moderate to severe persistent asthma who have inadequate control despite inhaled corticosteroids and additional controllers (e.g., LABA); considered a last-line adjunct. Clinical justification must document prior therapies and inadequate control.clinical

    Positioning based on rationale and trial data

    Chronic Idiopathic Urticaria (CIU) — trial eligibility-like criteria supported by CIU trials

    Covered when trial eligibility-like criteria are met as supported by CIU trials

    CIU trial-like criteria: Adults and adolescents with CIU with UAS7 ≥16 and weekly itch severity score ≥8 despite at least 2 weeks of H1 antihistamine therapy; approved doses 150 mg or 300 mg demonstrated efficacy (75 mg did not demonstrate consistent efficacy).clinical

    Derived from CIU pivotal trials

    Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) — trial-like criteria reflecting inadequate response to intranasal corticosteroids

    Covered when trial-like criteria reflecting inadequate response to intranasal corticosteroids are met

    CRSwNP trial-like criteria: Individuals with bilateral nasal polyps (NPS ≥5 with ≥2 in each nostril) and weekly average nasal congestion score >1 despite nasal mometasone; omalizumab demonstrated significant improvement in NPS and NCS at Week 24 in trials.clinical

    Background nasal mometasone required in trials

    IgE-mediated Food Allergy (supportive evidence)

    Covered stance informational — supportive randomized trial data in multi-food allergic individuals

    Food allergy evidence: Efficacy evaluated in the OUtMATCH trial (ages 1–55) in individuals allergic to peanut and at least two other foods; efficacy derived mainly from pediatric data with open-label extension supportive but uncontrolled; common adverse events include injection site reactions and fever.clinical

    Supportive evidence for select use cases

    Asthma - Initial Therapy

    Coverage is provided when indication-specific clinical criteria and FDA dosing/administration requirements are met; prior therapies and diagnostic thresholds vary by indication.

    Asthma coverage criteria (selected updates): Individual meets definition of moderate to severe persistent asthma AND has tried/failed appropriate controller therapy at maximum tolerated doses of inhaled corticosteroid (plus other controllers as clinically indicated) AND meets one of: (1) two or more exacerbations in previous 12 months requiring oral corticosteroids, (2) one or more exacerbations requiring hospitalization/ED/urgent care in previous 12 months, (3) FEV1 <80% predicted, OR (4) asthma that worsens upon tapering of oral corticosteroid therapy.see node text

    Concurrent use with certain biologics (e.g., Exdensur/depemokimab-ulaa) is not permitted.

    Chronic Idiopathic Urticaria - Initial Therapy

    Chronic idiopathic/spontaneous urticaria (CIU/CSU) coverage reflects FDA-labeled indications and trial-based dosing.

    CIU coverage criteria: Individual aged 12 or older with chronic idiopathic/spontaneous urticaria refractory to high-dose H1-antihistamine therapy AND provider documents inadequate response to prior antihistamines; dosing must comply with product labeling and not exceed 600 mg every 2 weeks.CIU dose limit 600 mg q2w

    Initial approval length updated to 12 months.

    Chronic Rhinosinusitis with Nasal Polyps - Initial Therapy

    Chronic rhinosinusitis with nasal polyps (CRSwNP) criteria updates.

    CRSwNP coverage criteria: Individual has inadequately controlled bilateral CRSwNP confirmed by physical exam, sinus CT, or nasal endoscopy AND has had prior systemic corticosteroids for nasal polyps within last 2 years, or a contraindication to systemic corticosteroids, or prior bilateral polyp surgery.two of: facial pressure/pain, moderate–severe nasal congestion/drainage/obstruction, or significant loss of smell

    Must follow FDA dosing/administration.

    Combination Therapy Exclusions

    Combination therapy exclusions

    Combination exclusions: Omalizumab is not to be used concurrently with specified biologics when used for the same indication (examples include tezepelumab/Tezspire, depemokimab-ulaa/Exdensur for asthma; dupilumab/Dupixent for nasal polyps).n/a

    Requests for concurrent use may be denied.

    Coverage and dosing criteria

    Coverage and dosing are determined using pretreatment total serum IgE and patient body weight; initial authorization duration is 12 months.

    Asthma dosing and authorization: For asthma, dosing is determined by pretreatment total serum IgE and body weight using the document dosing tables; dosing frequency is every 2 or 4 weeks as indicated. Initial authorization is for 12 months.see dosing tables (chunks 67-72)

    Do not use IgE measured during treatment for dose determination; re-test only if treatment interrupted ≥1 year.

    Chronic idiopathic/spontaneous urticaria dosing: For CIU/CSU, administer 150 mg or 300 mg subcutaneously every 4 weeks per labeling; dosing not dependent on serum IgE or body weight. Policy dose ceiling for CIU is 600 mg every 2 weeks (update).CIU dosing: 150 or 300 mg q4w; ceiling 600 mg q2w

    Initial authorization period updated to 12 months.

    IgE testing and interruptions:

    Dosing and administration rules

    Covered when dosing and clinical documentation follow product labeling and policy-specific restrictions

    Asthma dosing per table: Dosing for asthma is determined by body weight and baseline total serum IgE per the dosing table; administer every 2 or 4 weeks as indicated and adjust for significant weight changes.weight and baseline IgE per dosing table

    Do not use IgE tested during treatment for dose determination; re-test only after interruption >=1 year

    CIU dosing per label: Administer 150 mg or 300 mg subcutaneously every 4 weeks for chronic idiopathic urticaria; dosing is independent of serum IgE and weight.150 or 300 mg q4w

    CIU dosing ceiling updated in policy rationale; periodically reassess need for therapy

    Combination therapy exclusions: Omalizumab is not to be used concurrently with specified biologics (e.g., Dupixent, Tezspire, Depemokimab/Exdensur and other agents listed) for asthma or nasal polyps per policy updates.

    Omalizumab is designated investigational for uses not specifically listed as covered in this policy. Examples of indications considered investigational include allergic rhinitis, atopic dermatitis, other IgE‑mediated conditions, latex allergy, and bullous pemphigoid. Requests for these uses do not meet the policy's medical necessity criteria and should be denied unless supported by separate, specific coverage guidance.

    For chronic idiopathic urticaria (CIU), the policy notes that the 75 mg dose did not demonstrate consistent evidence of efficacy in pivotal CIU trials and is not an approved or supported dose for this indication. CIU dosing per labeling and policy is 150 mg or 300 mg every 4 weeks, with higher limits and frequency specified elsewhere only when supported by the product information and policy limits.

    The policy specifies that omalizumab should not be used in combination with certain other biologic therapies for the same indication. Notably, the policy prohibits concurrent use with tezepelumab (Tezspire/Exdensur/depemokimab-ulaa) when treating asthma and with dupilumab (Dupixent) when treating chronic rhinosinusitis with nasal polyps (CRSwNP). Such concurrent use is outside the policy's coverage rules and may be denied.

    The policy explicitly adds Exdensur (depemokimab-ulaa) to the list of agents that must not be used concurrently with omalizumab for the treatment of asthma. Concurrent administration of these agents for the same indication is not allowed under the updated coverage rules.

    Operationally, the policy enforces combination‑therapy exclusions across specified biologics. When omalizumab is requested for asthma or nasal polyps, coverage is contingent on not being used concurrently with the listed biologic agents (examples include tezepelumab/Exdensur, depemokimab-ulaa, dupilumab, mepolizumab, and others shown in the policy). Requests that propose simultaneous therapy with these agents for the same indication may be considered not medically necessary.

    The policy includes a site-of-service review. Administration in a hospital outpatient department or other non-preferred sites may be considered not medically necessary if the policy's site-of-service criteria are not met (for example, preferred sites, the first 90‑day guidance, distance to an outpatient infusion center, or specific high‑risk clinical conditions).

    The evidence and policy rationale reiterate that the 75 mg dose for CIU lacks consistent efficacy and is not supported by the clinical trial data; CIU dosing guidance remains centered on 150 mg or 300 mg every 4 weeks, with the policy's CIU dose ceiling updated to reflect a maximum of 600 mg every 2 weeks where applicable per the policy's revised limits.

    Providers must supply documentation that supports the absence of concurrent use with the biologics listed in the policy. Prior authorization and clinical records should explicitly state whether the patient is receiving any of the prohibited agents (for example, tezepelumab, depemokimab-ulaa, dupilumab, mepolizumab, remibrutinib, etc.); failure to document that omalizumab will not be combined with these agents may result in denial.

    The asthma dosing tables in the policy include explicit guidance for IgE/weight combinations and incorporate ‘DO NOT DOSE’ entries for certain very high pretreatment total serum IgE and body‑weight ranges (for example, specific >900–1,000 IU/mL ranges), indicating dosing is not recommended for those combinations.

    The policy update clarifies that concurrent combination therapy of omalizumab with the listed biologics for the same indication is not appropriate and may be denied. This operational restriction applies to treatment of both asthma and nasal polyps and reflects recent additions to the exclusion list.

    Coding and Dose Ranges

    HCPCS codes for omalizumab productsHCPCSCovered
    J2357Injection, omalizumab (Xolair), 5 mg.
    Q5154Injection, omalizumab-igec (Omlyclo), biosimilar, 5 mg (new code effective 10/01/25).
    Referenced product prescribing informationNDC | mixed
    NDCs referenced in PIProduct prescribing information references for Xolair and Omlyclo (NDCs not explicitly listed in this excerpt).
    Covered HCPCS CodesHCPCSCovered
    J2357Omalizumab injection
    inv-28: Total serum IgE ranges by age and indication — numeric limits and applicability
    Total serum IgE — ages 6–1230 IU/mL to 1,300 IU/mL
    Total serum IgE — ages ≥1230 IU/mL to 700 IU/mL
    ApplicabilityIgE thresholds used for asthma and CRSwNP dosing determination per indication-specific tables
    inv-29: Body weight range used for dosing tables — 20 kg to 150 kg as applicable
    Minimum body weight20 kg (44 lbs.)
    Maximum body weight150 kg (330 lbs.)

    Provider Actions, Prior Authorization, and Documentation

    Prior Authorization

    Obtain prior authorization; approvals can be up to 12 months

    Prior authorization is required for omalizumab products; initial approvals and reauthorizations may be granted for up to 12 months when medical necessity criteria and documentation of clinical response are provided.

    • Initial authorizations for all drugs in this policy may be approved up to 12 months.
    • Reauthorization for indications (asthma, CIU, CRSwNP, IgE-mediated food allergy) may be approved up to 12 months if medical necessity criteria are met and chart notes document continued clinical response (e.g., reduced exacerbations, improved symptoms, decreased itch/hives, decreased polyp size).
    Billing Rule

    Follow benefit-specific prior authorization and site-of-service rules

    Background and Product Information

    Background: Omalizumab is a recombinant, humanized anti‑IgE monoclonal antibody that binds free IgE and reduces IgE‑mediated allergic responses. It is used as add‑on maintenance therapy in conditions driven by IgE such as moderate‑to‑severe allergic asthma, chronic spontaneous (idiopathic) urticaria unresponsive to antihistamines, chronic rhinosinusitis with nasal polyps (CRSwNP), and in selected cases to reduce Type I reactions in IgE‑mediated food allergy. Coverage, dosing and administration follow FDA prescribing information and the policy's indication‑specific criteria.

    inv-57: Definition — IgE-mediated food allergy definition (informational)
    DefinitionAn allergic condition in which IgE antibodies recognize a food allergen and trigger rapid systemic allergic reactions (e.g., hives, swelling) after ingestion
    Clinical consequenceIgE-mediated reactions can be severe and involve histamine-mediated symptoms
    Policy contextOmalizumab may be considered to reduce Type I allergic reactions in individuals with documented IgE-mediated food allergy
    inv-58: Definition — Omalizumab (Xolair) product definition

    Policy Revision History

    2026-08-01policy_effective_dateLatest

    Policy effective date updated to 2026-08-01 with initial authorization for all reviews changed from 6 months to 12 months; chronic idiopathic urticaria dose limit set to 600 mg every 2 weeks and Exdensur (depemokimab-ulaa) added to asthma concurrency exclusions.

    2026-07-14administrative_revision

    Policy approved July 14, 2026; title changed from Xolair (omalizumab) to Omalizumab Products and Omlyclo (omalizumab-igec) was added with the same criteria as Xolair; site-of-service review added for Omlyclo.

    Policy Summary
    PayerPremera Bluecross
    PolicyOmalizumab Products (Xolair, Omlyclo) coverage
    Policy CodePolicy 5.01.513
    Change TypeClinical and operational updates (authorization length, dosing limits, combination exclusions)
    Effective DateAug 1, 2026
    Last ReviewJul 14, 2026
    Next Review DateJul 14, 2026
    Key ActionSubmit prior authorization with documentation of pretreatment total serum IgE and body weight and request initial approval for up to 12 months per updated policy.
    SourceLink
    On This Page
    Coverage Criteria for Omalizumab ProductsCoding and Dose RangesProvider Actions, Prior Authorization, and DocumentationBackground and Product InformationPolicy Revision History
    Dose cap: Dose limited to 600 mg every 2 weeks
    Concomitant biologics restriction: Not used in combination with dupilumab (Dupixent) or remibrutinib (Rhapsido) when used for chronic urticaria
    Prescriber: Prescribed by or in consultation with an allergist, immunologist, pulmonologist, or dermatologist as appropriate
    Prior therapy: Inadequate response or intolerance to intranasal corticosteroid monotherapy; medication prescribed in combination with intranasal corticosteroid
    Polyp history (one required): Prior systemic corticosteroids for nasal polyps in the last 2 years OR contraindication to systemic corticosteroids OR prior bilateral nasal polyp surgery
    Dose cap: Dose limited to 600 mg every 2 weeks based on serum IgE and body weight per prescribing table
    Concomitant biologics restriction: Not used with dupilumab, mepolizumab, or tezepelumab when used for CRSwNP
    Prescriber: Prescribed by or in consultation with an allergist, immunologist, or otolaryngologist (ENT)
    Dose limited to 600 mg every 2 weeks based on serum IgE and body weight per prescribing table
    Prescriber: Prescribed by or in consultation with an allergist, immunologist, or otolaryngologist
    Total IgE obtained during treatment cannot be used for dose determination because levels remain elevated up to 1 year after discontinuation; re-test for dosing only if treatment interrupted ≥1 year. Doses should be adjusted for significant weight changes.
    treatment interruption >= 1 year to re-test IgE

    See chunk 73 for details.

    concurrent use prohibited

    Requests for concurrent use may be denied

    ApplicabilityWeight ranges apply to dosing tables for asthma and CRSwNP; CIU dosing is independent of weight
    inv-30: UAS7 and itch severity thresholds used in CIU trials
    UAS7 thresholdUAS7 ≥16 prior to randomization
    Weekly itch severityWeekly itch severity score ≥8 for the 7 days prior to randomization
    Trial contextCriteria derived from pivotal CIU trials requiring at least 2 weeks of H1 antihistamine therapy prior to randomization
    inv-31: NPS and NCS requirements for CRSwNP documentation
    NPS requirementNPS ≥5 with NPS ≥2 in each nostril prior to randomization
    NCS requirementWeekly average nasal congestion score >1 despite nasal mometasone
    Measurement methodNPS measured endoscopically (0–4 per nostril; total 0–8)
    inv-32: CIU dosing limit — 600 mg every 2 weeks
    CIU dosing frequency capMaximum 600 mg every 2 weeks
    Label dosing for CIURecommended dosing per label also includes 150 mg or 300 mg every 4 weeks (efficacious doses)
    Policy noteDose ceiling updated in 2026 rationale; dosing must comply with product labeling
    inv-33: Asthma FEV1 threshold option — FEV1 <80% predicted
    FEV1 threshold optionFEV1 <80% predicted
    ContextOne of several asthma severity markers used to qualify for omalizumab (others include exacerbation history or oral steroid dependence)
    ApplicabilityUsed in moderate to severe persistent asthma coverage criteria
    inv-34: Dose tables based on pretreatment total serum IgE and body weight (multiple exact dosing thresholds enumerated)
    Dose tables basisDosing determined by pretreatment total serum IgE range and patient body weight
    Example IgE rangesRanges in tables include: 30–100, 100–200, 200–300, 300–400, 400–500, 500–600, 600–700, 700–800, 800–900, 900–1000, etc.
    Example mapped dosesMapped mg doses include 150 mg, 225 mg, 300 mg, 375 mg depending on IgE and weight and whether dosing every 2 or 4 weeks
    inv-35: IgE re-test interval — re-test >= 1 year after treatment interruption
    Re-test interval after interruption>= 1 year after treatment interruption
    RationaleTotal IgE remains elevated during treatment and up to one year after discontinuation; re-testing before 1 year is not valid for dose determination
    Dose determination after short interruptionIf interruption <1 year, use the serum IgE from the initial dose determination

    Omalizumab may be billed under either the pharmacy or medical benefit depending on the benefit management; prior authorization and administration-site requirements apply according to the benefit used.

    • Omalizumab is managed through both the pharmacy and medical benefits.
    • Prior authorization is implied where the applicable benefit requires it and site-of-service review may be applied for administration.
    Prior Authorization

    Request initial approval (standardized to 12 months) and expect site-of-service review when applicable

    Submit prior authorization requests using the policy-required clinical documentation and note that initial approvals are standardized to 12 months and may be subject to site-of-service review.

    • Initial approvals standardized to 12 months for all indications.
    • Site-of-service review may be applied when applicable (injection drugs subject to site-of-service criteria).
    • Providers must demonstrate medical necessity per indication to support a 12-month approval.
    Prior Authorization

    Expect 12-month initial authorizations

    Initial authorizations for omalizumab are granted for 12 months (policy updated from 6 months); request duration beyond this standard risks denial.

    • Policy updated initial authorization period from 6 months to 12 months for all reviews.
    • Requests inconsistent with the updated 12-month standard may be subject to denial review.
    Prior Authorization

    Ensure administrative requests reflect 12‑month initial authorizations

    Prior authorization is required per policy; administrative processes reflect the updated initial authorization length of 12 months for all reviews.

    • All drugs in this policy may be approved up to 12 months on initial authorization.
    • Operational updates removed non-formulary exception language and standardized authorization length.
    Step Therapy

    Document failure/intolerance to ≥2 high‑dose H1‑antihistamines for CIU

    For chronic idiopathic urticaria, document trial and failure or intolerance to at least two H1-antihistamines at high doses (up to 4× normal dosing) before requesting omalizumab.

    • Failed or intolerant to at least 2 H1-antihistamines in high doses (at least twice normal dosing and up to 4× normal dosing) or maximum tolerated dose.
    • Plan to continue a low dose of H1 antihistamines while on omalizumab.
    Note

    Justify omalizumab as last‑line add‑on for moderate–severe asthma

    Position omalizumab as an add‑on or last‑line option for moderate to severe persistent allergic asthma after optimization of inhaled corticosteroids and other controllers; include documentation of prior therapies.

    • Clinical justification should document use of prior standard therapies (inhaled corticosteroid at maximum tolerated dose plus additional controllers as indicated).
    • Policy frames omalizumab as an adjunct for individuals inadequately controlled despite these therapies.
    Step Therapy

    Document prior inadequate response to high‑dose H1‑antihistamines for CIU

    For CIU, the policy requires documentation of prior inadequate response to high‑dose H1‑antihistamine therapy before omalizumab is approved.

    • Provider must document inadequate response to high‑dose H1‑antihistamines.
    • CIU dosing must comply with product labeling and not exceed 600 mg every 2 weeks.
    Documentation Required

    Document prior controller therapies per appendix

    Include documentation of current controller therapies when requesting omalizumab for asthma (appendix lists relevant inhaled corticosteroids, long‑acting bronchodilators, leukotriene modifiers, and antihistamines).

    • Appendix lists inhaled corticosteroids (e.g., fluticasone, budesonide, mometasone), long‑acting bronchodilators (e.g., salmeterol), leukotriene modifiers, and antihistamines.
    • Document prior optimization and use of these background controller therapies in the medical record.
    Step Therapy

    Adhere to policy prior‑medication step requirements

    Follow the policy's prior medication requirements for CIU and asthma; document prior antihistamine trials for CIU and optimization of inhaled corticosteroids (maximum tolerated dose) for asthma per the current policy.

    • Providers must follow the current policy's specified prior medication requirements; earlier policy history documents prior steps but the current policy supersedes those.
    • Asthma criteria changed to 'maximum tolerated doses' of inhaled corticosteroids.
    • CIU requires prior antihistamine trials as described.
    Documentation Required

    Include complete office visit notes in the medical record submission

    Provide office visit notes that include the diagnosis, relevant history, physical exam, and detailed medication history when submitting medical necessity documentation.

    • Submit office visit notes documenting the diagnosis, relevant history, physical evaluation and medication history to support medical necessity.
    Documentation Required

    Document ≥3 in‑office doses and anaphylaxis risk assessment before self‑administration

    Document that at least three doses were administered in a health care provider's office and include the clinician's assessment of anaphylaxis risk and mitigation strategies before requesting self‑administration.

    • Omalizumab must be administered in a provider's office for at least 3 doses to establish safety.
    • Provider assessment of risk for anaphylaxis and mitigation strategies must be documented before approving self‑administration.
    Documentation Required

    Provide indication‑specific clinical documentation (exacerbations, FEV1, prior steroids/surgeries)

    Include diagnosis‑specific clinical documentation: for asthma, document exacerbation history, FEV1 results and systemic corticosteroid dependence/tapering issues; for CRSwNP document prior systemic steroid use or prior polyp surgery as applicable.

    • Asthma: document exacerbation history (e.g., ≥2 exacerbations requiring oral corticosteroids in prior 12 months), FEV1 results (e.g., <80% predicted), or worsening on steroid taper.
    • CRSwNP: document prior systemic corticosteroid use in last 2 years, contraindication to systemic steroids, or prior bilateral polyp surgery.
    • CIU: document inadequate response to prior antihistamines and duration ≥6 weeks.
    Documentation Required

    Record pretreatment total serum IgE and body weight for asthma dosing

    Document pretreatment total serum IgE and body weight used for dose determination for asthma; note that IgE measured during treatment is not valid for dosing decisions unless treatment was interrupted for ≥1 year.

    • Dose determination for asthma must be based on pretreatment total serum IgE and body weight using the dosing tables.
    • Re‑testing of IgE during treatment cannot be used for dose determination because total IgE remains elevated for up to one year after discontinuation; re‑test only if treatment interrupted ≥1 year.
    Documentation Required

    Provide required dosing documentation (IgE + weight for asthma; CIU dosing independent)

    For initial asthma dosing, document the serum total IgE and body weight and reference the policy's IgE/weight‑based dosing tables; for CIU, document that dosing is independent of IgE and weight.

    • Asthma: include serum total IgE and body weight and indicate the dose per the dosing table.
    • CIU: document that CIU dosing (150 or 300 mg q4w) does not require IgE or weight for dose selection.
    • Note re‑testing: use initial pretreatment IgE if interruption <1 year; re‑test only if interruption ≥1 year.
    Denial Risk

    Avoid site‑of‑service denials by meeting policy criteria

    Site‑of‑service requests may be denied if the request does not meet the policy's site‑of‑service criteria (preferred outpatient sites, first‑90‑day in‑office requirement, distance/home infusion availability, or increased‑risk clinical conditions).

    • Preferred medically necessary sites include physician's office, infusion center, or home infusion when criteria are met.
    • Hospital‑based outpatient settings are considered not medically necessary when site‑of‑service criteria are not met.
    • First 90 days of therapy or re‑initiation after ≥6 months commonly require office/infusion setting per policy.
    Denial Risk

    Ensure ≥3 in‑office administrations before self‑administration to avoid denial

    Failure to administer at least three doses in a provider office before considering self‑administration can trigger benefit management review or denial; document those in‑office administrations.

    • Omalizumab must be given in a health care provider's office for at least 3 doses to establish safety prior to self‑administration consideration.
    • Document the dates and assessments for those in‑office administrations.
    Denial Risk

    Avoid denials by following 12‑month authorization standard and combination exclusions

    Requests may be denied if they conflict with the policy's updated 12‑month standard or with combination‑therapy exclusions (concurrent use with certain biologics is prohibited).

    • Denial risk if requested authorization length exceeds the policy's updated 12‑month standard.
    • Denial risk if request proposes concurrent use of omalizumab with prohibited biologics (e.g., Tezspire/tezepelumab, Exdensur/depemokimab‑ulaa, Dupixent/dupilumab).
    Documentation Required

    Use only pretreatment IgE (or re‑test after ≥1 year off therapy) for dosing

    Do not base dose decisions on IgE tests obtained during omalizumab treatment because total IgE remains elevated for up to one year after discontinuation; use pretreatment IgE for dose determination or re‑test only after ≥1 year off therapy.

    • Re‑testing of IgE during treatment cannot be used for dose determination.
    • If treatment interrupted for <1 year, use the initial pretreatment IgE for dosing; re‑test for dose determination only after ≥1 year interruption.
    Denial Risk

    Do not combine omalizumab with listed biologics for the same indication

    Do not request concurrent use of omalizumab with specified biologics for the same indication; concurrent therapy with agents such as Tezspire (tezepelumab), Dupixent (dupilumab), or Depemokimab/Exdensur may trigger denial.

    • Policy explicitly restricts concurrent use with tezepelumab/Tezspire, depemokimab‑ulaa/Exdensur (asthma), and dupilumab/Dupixent (CRSwNP) among others.
    • Requests proposing combination biologic therapy for the same indication may be denied.
    Product descriptionXolair (omalizumab) is a recombinant, humanized anti-IgE monoclonal antibody that binds free IgE and reduces IgE-mediated allergic responses
    ManufacturingProduced in Chinese hamster ovary (CHO) cell culture
    MechanismInhibits binding of IgE to high-affinity FcεRI receptors on mast cells and basophils
    inv-59: Definition — Chronic idiopathic urticaria (CIU) definition
    DefinitionChronic idiopathic urticaria (CIU) is recurrent hives and itching without an identifiable external trigger, persisting despite antihistamine therapy
    Trial measuresClinical trials measure CIU severity with UAS7 and weekly itch severity scores
    Typical trial populationTrials included individuals aged 12 and older with longstanding disease and symptomatic UAS7 ≥16
    inv-60: Definition — Nasal Polyp Score (NPS) explanation
    NPS explainedNasal Polyp Score (NPS) is an endoscopic score 0–4 per nostril summed for total 0–8
    Scoring examples0=no polyps; 1=small polyps; 2=polyps reaching below lower border of middle turbinate; 3=large polyps; 4=complete obstruction
    Use in trialsNPS used to quantify polyp burden and eligibility (e.g., NPS ≥5 with ≥2 per nostril)
    inv-61: Definition — CIU/CSU clinical description and trial response context
    Clinical descriptionCIU/CSU is persistent hives and itching despite high-dose H1-antihistamine therapy
    Trial response contextPivotal trials showed greater decreases in itch and hive scores with 150 mg or 300 mg doses compared to placebo; 75 mg lacked consistent efficacy
    Regulatory noteFDA approved for ages 12 and older after failure of antihistamine therapy
    inv-62: Definition — Moderate to severe persistent asthma definition options
    Definition optionsModerate to severe persistent asthma may be defined by ≥2 exacerbations requiring oral corticosteroids in prior 12 months, OR ≥1 exacerbation requiring hospitalization/ED/urgent care, OR FEV1 <80% predicted, OR dependence on oral corticosteroids or worsening on taper
    Therapy contextUsed for individuals inadequately controlled despite maximum tolerated inhaled corticosteroid plus other controller therapies
    Age thresholdIndication includes individuals aged 6 years or older for asthma
    inv-63: Definition — CRSwNP diagnostic definition and prior therapy context
    Diagnostic definitionCRSwNP is bilateral nasal polyps confirmed by exam, sinus CT, or nasal endoscopy and inadequately controlled despite intranasal corticosteroids
    Prior therapy contextPolicy requires inadequate response to intranasal corticosteroid monotherapy and prior systemic corticosteroids within last 2 years OR contraindication OR prior bilateral polyp surgery
    Documentation noteObjective confirmation (endoscopy/CT) and NPS/NCS documentation per trials required
    inv-64: Definition — Xolair (omalizumab) product reference
    Product referenceXolair (omalizumab) — branded omalizumab product with prescribing information referenced
    SourceGenentech prescribing information cited in policy references
    Use in policyXolair listed with same criteria applied to Omlyclo in policy
    inv-65: Definition — Omlyclo (omalizumab-igec) product reference
    Product referenceOmlyclo (omalizumab-igec) — referenced omalizumab product (Celltrion) with prescribing information
    SourceOmlyclo prescribing information cited in policy references
    Policy applicationOmlyclo is included alongside Xolair and subject to same site-of-service and coverage criteria
    inv-66: Definition — CIU dosing (150 or 300 mg every 4 weeks) per label
    Label CIU dosing150 mg or 300 mg subcutaneously every 4 weeks per prescribing information
    Weight/IgE independenceCIU dosing is not dependent on serum total IgE or body weight
    Trial context150 mg and 300 mg demonstrated efficacy in CIU trials; 75 mg did not consistently show benefit
    inv-67: Definition — IgE testing guidance: levels remain elevated up to one year after discontinuation
    GuidanceTotal serum IgE remains elevated during treatment and for up to one year after discontinuation
    ImplicationIgE levels obtained during treatment cannot be used to determine dosing; re-test only after treatment interruption ≥1 year
    Dose-determination ruleIf interruption <1 year, use pretreatment IgE from initial dose determination
    2026-04-14
    annual_review

    Annual review approved April 14, 2026 updating initial authorization for all reviews from 6 months to 12 months and adding Exdensur (depemokimab-ulaa) to the list of medications not to be used concurrently for asthma.

    2025-10-03provider_notification_effective

    Policy changes (effective after 90-day provider notification) including addition of site-of-service review applicable to injection drugs became effective October 3, 2025.

    2025-08-12interim_review

    Interim review approved August 12, 2025; site-of-service medical necessity criteria clarified to apply to injection drugs.

    2025-01-13interim_review

    Interim review approved January 13, 2026 updating CRSwNP criteria and noting it will not be used in combination with Tezspire (tezepelumab) for that indication.